Nanotechnology based vaccines: Cervical cancer management and perspectives

Jasrotia, Ridhima; Dhanjal, Daljeet Singh; Bhardwaj, Sonali; Sharma, Parvarish; Chopra, Chirag; Singh, Reena; Kumar, Anupam; Mubayi, Anamika; Kumar, Deepak; Kumar, Raj; Goyal, Abhineet

doi:10.1016/j.jddst.2022.103351

Cited by 8 publications

(3 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are many nanotechnology-based COVID-19 vaccines that have been developed, and these vaccines can be categorized into three main classes based on their functional components: (a) virus particles, (b) viral protein-based, and (c) nucleic-acid-based [ 124 , 125 , 126 ]. Nanoparticles have manipulated and controlled properties and are nanoscale-sized particulate entities that resemble the structural characteristics of natural viruses.…”

Section: Nanotechnology-based Sars-cov-2 Vaccine Developmentmentioning

confidence: 99%

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

et al. 2023

Self Cite

View full text Add to dashboard Cite

Coronavirus, a causative agent of the common cold to a much more complicated disease such as “severe acute respiratory syndrome (SARS-CoV-2), Middle East Respiratory Syndrome (MERS-CoV-2), and Coronavirus Disease 2019 (COVID-19)”, is a member of the coronaviridae family and contains a positive-sense single-stranded RNA of 26–32 kilobase pairs. COVID-19 has shown very high mortality and morbidity and imparted a significantly impacted socioeconomic status. There are many variants of SARS-CoV-2 that have originated from the mutation of the genetic material of the original coronavirus. This has raised the demand for efficient treatment/therapy to manage newly emerged SARS-CoV-2 infections successfully. However, different types of vaccines have been developed and administered to patients but need more attention because COVID-19 is not under complete control. In this article, currently developed nanotechnology-based vaccines are explored, such as inactivated virus vaccines, mRNA-based vaccines, DNA-based vaccines, S-protein-based vaccines, virus-vectored vaccines, etc. One of the important aspects of vaccines is their administration inside the host body wherein nanotechnology can play a very crucial role. Currently, more than 26 nanotechnology-based COVID-19 vaccine candidates are in various phases of clinical trials. Nanotechnology is one of the growing fields in drug discovery and drug delivery that can also be used for the tackling of coronavirus. Nanotechnology can be used in various ways to design and develop tools and strategies for detection, diagnosis, and therapeutic and vaccine development to protect against COVID-19. The design of instruments for speedy, precise, and sensitive diagnosis, the fabrication of potent sanitizers, the delivery of extracellular antigenic components or mRNA-based vaccines into human tissues, and the administration of antiretroviral medicines into the organism are nanotechnology-based strategies for COVID-19 management. Herein, we discuss the application of nanotechnology in COVID-19 vaccine development and the challenges and opportunities in this approach.

show abstract

Section: Nanotechnology-based Sars-cov-2 Vaccine Developmentmentioning

confidence: 99%

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…There are several different types of cancer, but cervical cancer is the one that has emerged as the primary cause of death among females. The number of cervical cancer cases diagnosed is estimated to be around 500,000 annually ( Jasrotia et al, 2022 ). Based on their histology, cervical cancers are generally classified as squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma ( Jiang et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Darroudi

Nazari

Karimzadeh

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Introduction: Cervical cancer is the leading cause of cancer-related death in women, so novel therapeutic approaches are needed to improve the effectiveness of current therapies or extend their activity. In recent decades, graphene analogs, such as Mxene, an emerging class of two-dimensional (2D) graphene analogs, have been drawing considerable attention based on their intrinsic physicochemical properties and performance as potential candidates for tumor therapy, particularly for therapeutic purposes. Here we explored the targeted drug delivery in cervical cancer in in vivo model. Mxene-based nanocarriers are not able to be precisely controlled in cancer treatment.Method: To solve this problem, the titanium carbide-magnetic core-shell nanocarrier (Ti3C2-Fe3O4@SiO2-FA) is also developed to provide synergetic anticancer with magnetic controlling ability along with pH-responsive drug release. A xenograft model of the cervix was used to investigate the effects of Cisplatin alone, or in combination with Ti3C2@FA and Ti3C2@ Fe3O4@SiO2-FA, on tumor growth following histological staining for evaluation of necrosis.Result and Discussion: A significant tumor-growth suppression effect is shown when the Ti3C2-Fe3O4@SiO2-FA nanocarrier is magnetically controlled Cisplatin drug release. It reveals a synergistic therapeutic efficacy used in conjunction with pharmaceuticals (p < .001). According to the in vivo study, the Ti3C2@FA@Cisplatin nanocomposite exhibits less tumor growth than the drug alone or Ti3C2@FA@Cisplatin via increasing necrosis effect (p < .001). Through this study, Mxene nanosheets are expanded for biomedical applications, not only through the fabrication of biocompatible magnetic Mxene nanocomposite but also through the development of functionalization strategies that enable the magnetic Ti3C2 nanocomposite to load high levels of Cisplatin for cervical cancer treatment (242.5%). Hence, Ti3C2-Fe3O4@SiO2-FA nanocarriers would be promising candidates to improve cancer treatment efficiency.

show abstract

“…According to the World Health Organization (WHO), cervical cancer is the fourth most common cancer among women aged 15 to 44 in the world, with 604,000 and 342,000 worldwide cases of morbidity and death, respectively, in 2020 [ 5 , 6 ]. Statistics show that in 2020, there were about 110,000 new cases of cervical cancer and 59,000 deaths in China [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Factors Influencing Men’s Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program

et al. 2022

View full text Add to dashboard Cite

Background: Human papillomavirus (HPV) infection is the most common sexually transmitted disease, and it is associated with anogenital warts and oropharyngeal and anogenital cancers. Among female malignant tumors in China, the incidence of cervical cancer ranks second, with only breast cancer being more prevalent. HPV infection and related diseases affects both women and men. HPV vaccination is an optimal prevention strategy in preventing HPV infection and related diseases. The inclusion of the HPV vaccine in the national immunization program is an effective way to increase immunization coverage, reduce the burden of HPV related diseases, and increase national life expectancy. Objective: This study aimed to explore the factors influencing the attitudes of Chinese men toward the inclusion of the HPV vaccine in males included in the national immunization program, thus providing reference for launching the national immunization program policy. Methods: We invited men aged 20 to 45 to participate in an online survey. The participants were requested to complete a questionnaire, including sociodemographic characteristics, sexual behavior characteristics, knowledge of HPV and the HPV vaccine, and attitudes toward the HPV vaccine. A logistic regression model was constructed to analyze the influencing factors of attitudes. Results: A total of 660 males in China participated in this survey, and 80.45% supported the inclusion of HPV vaccines in national immunization programs. Participants earning CNY 100,000–200,000 (dds ratio (OR): 0.63, 95% confidence interval (CI): 0.39–1.00) or ≥200,000 (OR: 0.34, 95% CI: 0.17–0.68) were more likely to disapprove this strategy. Compared with people without a history of HPV infection, those with a history of HPV infection (OR: 1.84, 95% CI: 1.17–2.90) were more likely to approve. Men who had better knowledge of HPV were more likely to approve than men with less knowledge about HPV (OR: 1.44, 95% CI: 1.17–1.79). Compared with participants who did not know when the HPV vaccine should be given, those who knew that the ideal time of vaccination is before an individual becomes sexually active (OR: 1.75, 95% CI: 1.04–2.95) were more likely to approve. Conclusion: One in five men did not support the inclusion of HPV vaccines in national immunization programs, and they are likely to be from higher socioeconomic background and have poor knowledge of HPV. In order to implement comprehensive immunity, targeted actions need to be taken at national and public levels. In addition, when implementing measures, more attention needs to be paid to lower income men, men without a history of HPV infection and with poor knowledge of HPV, as well as young men.

show abstract

Nanotechnology based vaccines: Cervical cancer management and perspectives

Cited by 8 publications

References 164 publications

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Factors Influencing Men’s Attitudes toward HPV Vaccination in Males Included in the Chinese National Immunization Program

Contact Info

Product

Resources

About